Literature DB >> 10495106

Presenilins: structural aspects and posttranslational events.

F Checler1.   

Abstract

Most of early-onset forms of Alzheimer's disease (AD) are caused by inherited mutations located on chromosomes 14 and 1, the gene products of which have been recently identified and referred to as presenilins 1 (PS1) and 2 (PS2), respectively. The first phenotypic alterations triggered by mutated PS were reported to be an increased production of the amyloid peptide (Abeta) and, more precisely, its 42 amino-acids long counterpart Abeta42. This overproduction is thought to be responsible for the genesis of the senile plaques that invade the cortical and subcortical areas of these AD-affected brains. The discovery of PSs has triggered numerous studies aimed at better understanding their normal physiology and the dysfunctions brought by the mutations that could explain, at least in part, the neurodegenerative process taking place in this syndrome. In this review, I will focus on the structural aspects of PS and on the various posttranscriptional events they undergo. I will also briefly discuss that current hypotheses concerning their normal functions and the influence of FAD-linked mutations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495106     DOI: 10.1007/BF02821716

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  88 in total

1.  Different effects of Alzheimer-associated mutations of presenilin 1 on its processing.

Authors:  O Murayama; T Honda; M Mercken; M Murayama; K Yasutake; N Nihonmatsu; Y Nakazato; G Michel; S Song; K Sato; H Takahashi; A Takashima
Journal:  Neurosci Lett       Date:  1997-06-20       Impact factor: 3.046

2.  Cell surface expression of the Alzheimer disease-related presenilin proteins.

Authors:  N N Dewji; S J Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins.

Authors:  B De Strooper; M Beullens; B Contreras; L Levesque; K Craessaerts; B Cordell; D Moechars; M Bollen; P Fraser; P S George-Hyslop; F Van Leuven
Journal:  J Biol Chem       Date:  1997-02-07       Impact factor: 5.157

4.  Immunohistochemical analysis of presenilin-1 expression in the mouse brain.

Authors:  S Moussaoui; C Czech; L Pradier; V Blanchard; B Bonici; M Gohin; A Imperato; F Revah
Journal:  FEBS Lett       Date:  1996-04-01       Impact factor: 4.124

5.  Transcriptional regulation of the mouse presenilin-1 gene.

Authors:  N Mitsuda; A D Roses; M P Vitek
Journal:  J Biol Chem       Date:  1997-09-19       Impact factor: 5.157

6.  Cellular expression and proteolytic processing of presenilin proteins is developmentally regulated during neuronal differentiation.

Authors:  A Capell; R Saffrich; J C Olivo; L Meyn; J Walter; J Grünberg; P Mathews; R Nixon; C Dotti; C Haass
Journal:  J Neurochem       Date:  1997-12       Impact factor: 5.372

7.  Identification of caspases that cleave presenilin-1 and presenilin-2. Five presenilin-1 (PS1) mutations do not alter the sensitivity of PS1 to caspases.

Authors:  M van de Craen; C de Jonghe; I van den Brande; W Declercq; G van Gassen; W van Criekinge; I Vanderhoeven; W Fiers; C van Broeckhoven; L Hendriks; P Vandenabeele
Journal:  FEBS Lett       Date:  1999-02-19       Impact factor: 4.124

8.  Protein topology of presenilin 1.

Authors:  A Doan; G Thinakaran; D R Borchelt; H H Slunt; T Ratovitsky; M Podlisny; D J Selkoe; M Seeger; S E Gandy; D L Price; S S Sisodia
Journal:  Neuron       Date:  1996-11       Impact factor: 17.173

9.  Identification and neuron specific expression of the S182/presenilin I protein in human and rodent brains.

Authors:  G A Elder; N Tezapsidis; J Carter; J Shioi; C Bouras; H C Li; J M Johnston; S Efthimiopoulos; V L Friedrich; N K Robakis
Journal:  J Neurosci Res       Date:  1996-08-01       Impact factor: 4.164

10.  Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells.

Authors:  D M Kovacs; H J Fausett; K J Page; T W Kim; R D Moir; D E Merriam; R D Hollister; O G Hallmark; R Mancini; K M Felsenstein; B T Hyman; R E Tanzi; W Wasco
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

View more
  2 in total

Review 1.  The mitochondrial permeability transition in neurologic disease.

Authors:  M D Norenberg; K V Rama Rao
Journal:  Neurochem Int       Date:  2007-03-04       Impact factor: 3.921

2.  Targeting γ-secretase triggers the selective enrichment of oligomeric APP-CTFs in brain extracellular vesicles from Alzheimer cell and mouse models.

Authors:  Inger Lauritzen; Anaïs Bécot; Alexandre Bourgeois; Raphaëlle Pardossi-Piquard; Maria-Grazia Biferi; Martine Barkats; Fréderic Checler
Journal:  Transl Neurodegener       Date:  2019-12-05       Impact factor: 8.014

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.